Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T19:43:46.951Z.
Calculation as of: 2026-10-06T19:43:46.951Z.
Quote observation: 2026-10-06T19:40:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b864e21534e19d3622fdd1df0bfa06a86802ee3b4002ae0b13a65066f94ec11b
PE RATIO
N/A
Market Cap
$2.11B
PE Ratio
19.80
TTM Avg
21.19
3Y Avg
24.83
5Y Avg
28.15
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | $2.06B | N/A | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | N/A | N/A | N/A | N/A |
| Vericel Corporation (VCEL)vs › | $2.05B | 85.58 | 135.31 | 1187.07 | 1145.73 |
| Alvotech (ALVO)vs › | $2.07B | N/A | 33.55 | 33.55 | 33.55 |
| Vera Therapeutics, Inc. (VERA)vs › | $2.09B | N/A | N/A | N/A | N/A |
| Progyny, Inc. (PGNY)vs › | $2.03B | 28.17 | 33.84 | 41.30 | 55.21 |
| UroGen Pharma Ltd. (URGN)vs › | $2.02B | N/A | 200.96 | 200.96 | 200.96 |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.02B | N/A | 7.63 | 7.63 | 7.63 |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 19.80 | 21.19 | 24.83 | 28.15 |
| Fortrea Holdings Inc. (FTRE)vs › | $2.00B | N/A | 34.42 | 34.42 | 34.42 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$18.15
Forward EPS (Est.)
$-3.92
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
